{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Endometrial+Cancer&page=2",
    "query": {
      "condition": "Recurrent Endometrial Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Endometrial+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:00:24.545Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03564340",
      "title": "Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Ovarian Cancer",
        "Recurrent Fallopian Tube Cancer",
        "Recurrent Primary Peritoneal Cancer",
        "Recurrent Endometrial Cancer",
        "Endometrial Cancer",
        "Low-grade Serous Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Ubamatamab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 890,
      "start_date": "2018-05-21",
      "completion_date": "2027-05-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-05-22T04:00:24.545Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03564340"
    },
    {
      "nct_id": "NCT00082823",
      "title": "Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "ziv-aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 25,
      "start_date": "2004-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-05-22T04:00:24.545Z",
      "location_count": 2,
      "location_summary": "New York, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082823"
    },
    {
      "nct_id": "NCT06349642",
      "title": "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Early Stage Triple-Negative Breast Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Cervical Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Esophageal Carcinoma",
        "Metastatic Liver Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Skin Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Resectable Lung Non-Small Cell Carcinoma",
        "Early Stage Lung Non-Small Cell Carcinoma",
        "Resectable Malignant Solid Neoplasm",
        "Resectable Triple-Negative Breast Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Recurrent Cervical Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Esophageal Carcinoma",
        "Recurrent Liver Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Recurrent Malignant Skin Neoplasm",
        "Recurrent Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Tissue Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2024-04-24",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-05-22T04:00:24.545Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06349642"
    },
    {
      "nct_id": "NCT03345485",
      "title": "Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Soft Tissue Sarcoma",
        "Triple-negative Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Tinostamustine 60mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 100mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 60mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 100mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 80min",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mundipharma Research Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2017-11-08",
      "completion_date": "2023-03-29",
      "has_results": true,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-05-22T04:00:24.545Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345485"
    },
    {
      "nct_id": "NCT03015129",
      "title": "A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Cancer",
        "Endometrial Carcinosarcoma",
        "Endometrial Carcinoma",
        "Endometrial Cancer Recurrent",
        "Endometrial Carcinoma, Recurrent"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 80,
      "start_date": "2017-01",
      "completion_date": "2022-12-30",
      "has_results": true,
      "last_update_posted_date": "2024-02-06",
      "last_synced_at": "2026-05-22T04:00:24.545Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03015129"
    },
    {
      "nct_id": "NCT03555422",
      "title": "Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo for selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 263,
      "start_date": "2018-01-05",
      "completion_date": "2025-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-22T04:00:24.545Z",
      "location_count": 19,
      "location_summary": "Tucson, Arizona • Palo Alto, California • Tampa, Florida + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03555422"
    },
    {
      "nct_id": "NCT01225887",
      "title": "Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Mucinous Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Squamous Cell Carcinoma",
        "Endometrial Transitional Cell Carcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm",
        "Recurrent Uterine Corpus Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 37,
      "start_date": "2011-10",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-10-09",
      "last_synced_at": "2026-05-22T04:00:24.545Z",
      "location_count": 59,
      "location_summary": "Burbank, California • Aurora, Colorado • Hartford, Connecticut + 40 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01225887"
    },
    {
      "nct_id": "NCT01164735",
      "title": "Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Recurrent Uterine Corpus Carcinoma",
        "Stage III Uterine Corpus Cancer",
        "Stage IV Uterine Corpus Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 169,
      "start_date": "2010-01",
      "completion_date": "2018-01",
      "has_results": false,
      "last_update_posted_date": "2024-08-14",
      "last_synced_at": "2026-05-22T04:00:24.545Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01164735"
    },
    {
      "nct_id": "NCT05603910",
      "title": "Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Endometrial Carcinoma",
        "Unresectable Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Hypofractionated External Beam Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Aaron Wolfson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2023-04-15",
      "completion_date": "2030-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-05-22T04:00:24.545Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05603910"
    },
    {
      "nct_id": "NCT04196257",
      "title": "BP1001-A in Patients With Advanced or Recurrent Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Carcinoma, Ovarian Epithelial",
        "Fallopian Tube Neoplasms",
        "Endometrial Cancer",
        "Peritoneal Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)",
          "type": "DRUG"
        },
        {
          "name": "BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bio-Path Holdings, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2022-08-19",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2025-03-07",
      "last_synced_at": "2026-05-22T04:00:24.545Z",
      "location_count": 4,
      "location_summary": "Silver Spring, Maryland • Detroit, Michigan • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04196257"
    }
  ]
}